Biogen on Twitter: "Jean-Paul Kress, MD, joins Biogen today as EVP & President, International & Head, Global Therapeutic Operations https://t.co/bJaIERREZ3 https://t.co/BMu0PTC99l" / Twitter
Dr. Jean-Paul Kress is new CEO of MorphoSys AG - Innovations- und Gründerzentrum Biotechnologie IZB
MorphoSys acquires Constellation Pharma for $1.7B - Boston Business Journal
MorphoSys pivots business model; Africa's vaccine financing gap | S&P Global Market Intelligence
Jean-Paul Kress, Morphosys AG: Profile and Biography - Bloomberg Markets
Jean-Paul Kress M.D. — Executive VP, President of International, Head of Global Therapeutic Operations at Biogen | Comparably
Morphosys: Das sind die Ziele von CEO Kress & Co - DER AKTIONÄR
MS Therapies are Focus of Abarca-Biogen Value-based Reimbursement Contract
Jean-Paul Kress, M.D. | Morphosys de
Samsung, Biogen version of AbbVie's Humira approved in Europe | Reuters
Jean-Paul Kress - CEO - MorphoSys | LinkedIn
Abarca Health, Biogen ally on multiple sclerosis coverage – News is My Business
Jean-Paul Kress email address & phone number | Morphosys Chairman of the Board of Management, Chief Executive Officer contact information - RocketReach
New CEO at Morphosys - European Biotechnology
Jean-Paul Kress M.D. — Executive VP, President of International, Head of Global Therapeutic Operations at Biogen | Comparably
Kress becomes new CEO of MorphoSys - BioM
Jean-Paul Kress - CEO - MorphoSys | LinkedIn
Jean-Paul Kress email address & phone number | Morphosys Chairman of the Board of Management, Chief Executive Officer contact information - RocketReach
Chutes & Ladders—Biogen executive Kress takes over the reins of Syntimmune | Fierce Biotech
Two by 2025: MorphoSys Consolidates Research, Retains Commercialization Goal
Exhibit 99.1
